{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T22:08:24Z","timestamp":1782598104643,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001203","name":"GlaxoSmithKline Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000555","name":"British Microcirculation Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000555","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.euo.2019.06.017","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T08:17:35Z","timestamp":1563524255000},"page":"548-554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Management of Patients with Normal Cystoscopy but Positive Cytology or Urine Markers"],"prefix":"10.1016","volume":"3","author":[{"given":"Joan","family":"Palou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Brausi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.F.","family":"Catto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2019.06.017_bib0125","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.eururo.2012.09.057","article-title":"ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers","volume":"63","author":"Kamat","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2019.06.017_bib0130","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/01.ju.0000134347.14643.ab","article-title":"A side by side comparison of cytology and biomarkers for bladder cancer detection","volume":"172","author":"Schroeder","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2019.06.017_bib0135","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bju.13760","article-title":"Guideline of guidelines\u2014non-muscle invasive bladder cancer","volume":"119","author":"Woldu","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2019.06.017_bib0140","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2019.06.017_bib0145","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2019.06.017_bib0150","series-title":"European Association of Urology (EAU) guidelines on non-muscle-invasive bladder cancer (NMIBC), TaT1 and carcinoma in situ (CIS): 2019 update","author":"Babjuk","year":"2019"},{"key":"10.1016\/j.euo.2019.06.017_bib0155","doi-asserted-by":"crossref","first-page":"1162.e1","DOI":"10.1016\/j.urology.2012.06.035","article-title":"Confocal laser endomicroscopy of bladder tumours associated with photodynamic diagnosis: an ex vivo pilot study","volume":"80","author":"Bonnal","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.euo.2019.06.017_bib0160","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.euf.2017.05.008","article-title":"Correlation between confocal laser endomicroscopy (Cellvizio\u00ae) and histological grading of upper tract urothelial carcinoma: a step forward for a better selection of patients suitable for conservative management","volume":"4","author":"Breda","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2019.06.017_bib0165","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.juro.2016.03.194","article-title":"Upper urinary tract carcinoma in situ: current knowledge, future direction","volume":"197","author":"Redrow","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2019.06.017_bib0170","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1002\/cncr.25903","article-title":"Assessing the clinical benefit of NMP22 in the surveillance of patients with non-muscle-invasive bladder cancer and negative cytology: a decision-curve analysis","volume":"117","author":"Shariat","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2019.06.017_bib0175","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.295.3.299","article-title":"Surveillance for recurrent bladder cancer using a point-of-care proteomic assay","volume":"295","author":"Grossman","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2019.06.017_bib0180","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1038\/sj.onc.1209209","article-title":"Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls","volume":"25","author":"Yates","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.euo.2019.06.017_bib0185","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/bjc.2012.221","article-title":"An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer","volume":"107","author":"Miah","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2019.06.017_bib0190","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.urolonc.2010.02.011","article-title":"Statistical consideration for clinical biomarker research in bladder cancer","volume":"28","author":"Shariat","year":"2010","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2019.06.017_bib0195","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.eururo.2013.02.036","article-title":"Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers","volume":"64","author":"Bangma","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2019.06.017_bib0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14040","article-title":"Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer","volume":"14","author":"Mowatt","year":"2010","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.euo.2019.06.017_bib0205","unstructured":"PHOTO trial. https:\/\/w3.abdn.ac.uk\/hsru\/photo\/."},{"key":"10.1016\/j.euo.2019.06.017_bib0210","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","article-title":"Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data","volume":"64","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2019.06.017_bib0215","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2013.09.049","article-title":"Bacillus Calmette-Gu\u00e9rin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra","volume":"65","author":"Giannarini","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2019.06.017_bib0220","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0302-2838(02)00006-4","article-title":"Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis","volume":"41","author":"Raitanen","year":"2002","journal-title":"Eur Urol"},{"issue":"Suppl. 2","key":"10.1016\/j.euo.2019.06.017_bib0225","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1038\/modpathol.2008.193","article-title":"Diagnosis of urothelial carcinoma from urine","volume":"22","author":"Tetu","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.euo.2019.06.017_bib0230","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00345-018-2380-x","article-title":"An up-to-date catalog of available urinary biomarkers for the surveillance of non muscle invasive bladder cancer","volume":"36","author":"Soria","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2019.06.017_bib0235","doi-asserted-by":"crossref","first-page":"531.e15","DOI":"10.1016\/j.urolonc.2017.03.008","article-title":"Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma","volume":"35","author":"Lotan","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2019.06.017_bib0240","doi-asserted-by":"crossref","first-page":"811","DOI":"10.7150\/ijms.19929","article-title":"Urinary UBC Rapid and NMP22 Test for bladder cancer surveillance in comparison to urinary cytology: results from a prospective single-center study","volume":"14","author":"Pichler","year":"2017","journal-title":"Int J Med Sci"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931119300987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931119300987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:47:17Z","timestamp":1762876037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931119300987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S2588931119300987"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2019.06.017","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Patients with Normal Cystoscopy but Positive Cytology or Urine Markers","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2019.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}